Fatty liver disease is one of the most common health problems in the world, and also one of the quietest. Millions of people live with fat building up in their liver and feel perfectly well. The danger is not the fat itself in the early stages. It is what can follow: inflammation, scarring, and in some people, serious liver damage that is only found late, when treatment options are narrower.
That is why a study reported on 1 November 2026 has caught attention. Researchers compared 30 blood tests and test combinations for fatty liver disease, and one single blood protein stood out for spotting the more advanced, risky stages of the condition. The protein is called thrombospondin-2, or TSP2 for short. The result does not mean a simple blood test can now replace a liver biopsy, and it does not mean a new treatment has arrived. But it does point to a future in which checking liver health could become cheaper and simpler.
This article explains what the study actually found, what it did not find, and what it could mean for ordinary readers. It is general health information only, not medical advice. If you are worried about your liver, speak to your own doctor, who knows your history and can decide which tests, if any, are right for you.
Fatty liver, explained in plain language
Doctors now call the most common form of fatty liver disease MASLD, short for metabolic dysfunction-associated steatotic liver disease. The older name was non-alcoholic fatty liver disease. In MASLD, excess fat collects in liver cells in people who often also have other metabolic problems, such as type 2 diabetes, high blood pressure, raised cholesterol, or excess weight around the waist.
For many people, MASLD stays stable and causes no symptoms. In others, the liver becomes inflamed. That more active stage is called MASH, short for metabolic dysfunction-associated steatohepatitis. Over years, ongoing inflammation can lead to fibrosis, which is scarring of the liver tissue. Advanced scarring, and eventually cirrhosis, can seriously affect how the liver works.
The hard part for doctors has always been staging: working out where a person sits on that path. Two people can have similar blood results on routine tests yet very different levels of liver scarring. Until now, the most reliable way to confirm the stage has often been a liver biopsy, in which a small tissue sample is taken with a needle and examined under a microscope. A biopsy is accurate, but it is invasive, it carries a small risk of complications, it can be uncomfortable, and it cannot realistically be offered to everyone with fatty liver. That gap is exactly what blood-based tests are trying to fill.
What the LITMUS study did
The new findings come from the LITMUS study, whose full name is Liver Investigation: Testing Marker Utility in Steatohepatitis. It was a large, prospective, multi-centre study, which means researchers followed a plan in advance, across many hospitals, rather than looking back at old records.
The study analysed data from 1,590 patients with MASLD whose diagnosis had been confirmed by liver biopsy, so the researchers knew the true stage of each person's disease when they tested the blood markers against it. Participants were enrolled between 2018 and 2023 at 37 liver centres in 13 countries across Europe and the United States. That size and spread matter: a test that only works in one hospital or one small group is far less useful than one that holds up across different clinics.
Against that biopsy-confirmed standard, the team compared 30 individual biomarkers and test combinations. Some of the combinations also involved elastography, a specialised ultrasound technique that estimates liver stiffness, which rises as scarring increases.
The headline result was about TSP2. Developed and fully validated by the Institute of Translational Immunology at University Medical Center Mainz, TSP2 is a connective tissue protein. Its concentration in the blood gives a reliable indication of fibrotic changes in liver tissue, the kind of scarring linked to a risk of cirrhosis.
What TSP2 did well, and where it fell short
Good science reporting needs both halves of the story, and this study has a clear limit that the researchers themselves state. None of the tests, including TSP2, reached the study's pre-set threshold for diagnosing early-stage fatty liver disease without significant scarring. In other words, the tests were strong where the stakes are highest — advanced scarring and cirrhosis — but not yet good enough to reliably pick up the earliest stages on their own.
That distinction matters for how the test might be used. A test that is good at finding advanced disease is valuable for prioritising care: it can help doctors decide who needs closer monitoring, specialist referral, or more detailed imaging, and who can safely continue with routine follow-up. It is not the same as a screening test for everyone, and it does not replace clinical judgement.
It is also worth noting what TSP2 is not. It is a marker, not a medicine. A higher TSP2 level does not treat the liver. What it offers is information: a non-invasive, relatively inexpensive signal that could help doctors sort patients by risk without sending everyone for a biopsy.
Why a blood test could change everyday care
If a reliable blood marker for advanced fatty liver disease becomes part of routine practice, several practical things could change. First, testing could reach far more people. A blood draw is quick and available in clinics everywhere, while a biopsy requires a specialist setting and recovery time. Second, monitoring could become easier: doctors could repeat a blood test over time to track whether a patient's risk profile is stable or worsening.
Third, it could help close a gap in who gets diagnosed. Fatty liver disease is often found by chance, when a routine blood test shows raised liver enzymes, or when an ultrasound done for another reason shows a fatty liver. Many cases are missed because routine liver enzymes can look normal even when scarring is present. A marker aimed specifically at fibrosis could catch some of those missed cases earlier, when lifestyle changes still have the most room to help.
Readers interested in how everyday habits shape metabolic health may also find our look at the science of sleep debt useful, since poor sleep is one of the overlooked factors that can push weight, appetite, and blood sugar in the wrong direction. Similarly, the story of why weight returns after GLP-1 drugs stop is a reminder that metabolic conditions are rarely fixed by a single intervention, and that long-term habits matter more than any one test or treatment.
What this does not mean yet
It is easy to over-read a single study, so here is what should not be claimed from this one. TSP2 is not yet a routine test your doctor can simply order tomorrow in every country. The study is a strong validation step, not a launch announcement. Regulators, laboratories, and clinical guidelines would need to weigh in before it becomes standard practice, and costs, availability, and cut-off values for different populations would need to be settled.
Nor does a promising marker mean that everyone with fatty liver needs urgent testing. Many people with MASLD have mild disease and a low short-term risk. Doctors weigh age, diabetes status, weight, alcohol use, other illnesses, and existing test results when deciding who needs further investigation. A new marker fits into that judgement; it does not replace it.
There is also a research caveat. The LITMUS participants were patients already attending liver centres and diagnosed by biopsy, so they may differ from the general population visiting a family doctor. Further studies in primary care settings will be needed to confirm how TSP2 behaves there. And one study is not a consensus: other teams, in other countries, will need to replicate the result in new groups of patients.
Practical steps readers can take now
While TSP2 testing is not yet routine, the steps that protect liver health are already well established, and they overlap heavily with general metabolic health. If you have risk factors — type 2 diabetes, excess weight, high cholesterol, or high blood pressure — it is reasonable to ask your doctor whether your liver has been checked.
From there, the everyday measures are familiar, but worth restating because they genuinely work. Aim for gradual, sustainable weight loss if you carry excess weight, rather than crash diets. Build movement into the day: walking, cycling, or any activity you enjoy and will repeat. Keep alcohol low or avoid it, since alcohol adds liver strain on top of metabolic fat. Eat a pattern rich in vegetables, whole grains, legumes, and unsaturated fats, and be cautious with sugary drinks and heavily processed foods.
Research on omega-3 EPA after bowel cancer surgery is a useful parallel here: it shows how an early, promising finding still needs larger trials and careful follow-up before it changes everyday care. The same discipline applies to TSP2. Promising is not the same as proven for routine use, and patience is part of good medicine.
What to watch next
Three developments will show whether TSP2 moves from research finding to everyday tool. The first is independent replication in primary care and in more diverse populations. The second is practical: whether laboratories can offer the test reliably and affordably, and whether guidelines set clear thresholds for action. The third is combination: whether TSP2 works even better alongside other markers or imaging, such as elastography, to give doctors a fuller picture without a biopsy.
There is also a bigger question worth watching. As fatty liver disease becomes more common worldwide, driven by rising rates of obesity and diabetes, health systems will need cheap, scalable ways to find the minority of patients heading toward serious liver damage. Blood markers like TSP2, alongside imaging and risk scores, are the most realistic route to that goal.
The bottom line
A large international study, reported on 1 November 2026, found that a single blood protein, TSP2, performed well for identifying advanced scarring and cirrhosis in fatty liver disease, outperforming other single markers among 30 tests compared against biopsy-confirmed diagnoses in 1,590 patients. It did not clear the bar for early-stage disease, and it is not yet a routine clinical test. But as a step toward non-invasive, inexpensive liver assessment, it is one of the more encouraging fatty liver findings of recent years.
This article is general health information only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your doctor or another qualified health professional with any questions about a medical condition.